Bleeding disorder prevalence is boosting the Corifact Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Corifact Market During The Forecast Period 2026–2030?

Historically, growth was primarily driven by the increased awareness of fibrinogen deficiency, alongside significant advancements in trauma care, enhanced surgical bleeding management protocols, the approval of plasma-derived therapies, and their widespread adoption by hospitals.

The anticipated growth during the forecast period is primarily fueled by an increase in emergency surgical procedures, the requirements of an aging demographic, the expansion of trauma centers, advancements in coagulation diagnostic methods, and a rising demand for swift-acting hemostatic agents. Concurrently, significant developments anticipated in this period include a greater reliance on fibrinogen concentrates, an intensified focus on quickly managing bleeding, an expansion in trauma and surgical healthcare services, the implementation of hospital-centric hemostasis management strategies, and an increasing application in the treatment of liver diseases.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Economic Or Industry Drivers Are Impacting The Corifact Market?

The expanding occurrence of bleeding disorders is projected to boost the corifact market’s future growth. These conditions hinder the blood’s proper clotting, resulting in excessive or prolonged bleeding. The uptick in bleeding disorders stems from enhanced diagnosis, greater public awareness, advancements in genetic testing, alongside evolving lifestyles and existing underlying health issues. Corifact addresses bleeding disorders stemming from factor XIII deficiency by substituting the absent clotting factor, thus assisting in the formation of stable blood clots and mitigating excessive bleeding. For example, in December 2023, a report from the UK-based United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) highlighted the prevalence of bleeding disorders in 2023/24, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the rising incidence of bleeding disorders is fueling the expansion of the corifact market. An increased demand for biological products is anticipated to spur the future growth of the corifract market. Biological products are intricate pharmaceutical compounds originating from living organisms, utilized for diagnosing, preventing, treating, and curing various illnesses and medical conditions. This surge in demand for biological products is linked to escalating environmental worries, enhanced consumer consciousness, and the necessity for sustainable and efficient substitutes for synthetic chemicals. Corifract aids biological products by boosting their stability, bioavailability, and effectiveness, thereby guaranteeing peak performance and extended shelf life through cutting-edge formulation and delivery methods. As an illustration, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, reported that biosimilar net revenue could range from a USD 33.5 million deficit in smaller markets to USD 9.5 billion in larger markets. Furthermore, proposed regulatory revisions, such as universal interchangeability, a global comparator, and the elimination of comparative efficacy studies, are projected to reduce development costs and elevate lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the growing demand for biological products is propelling the corifract market.

What Market Segments Are Evaluated Within The Corifact Market?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Who Are The Top Market Participants Influencing The Corifact Market?

Major companies operating in the corifact market are CSL Behring

Read the full corifact market report here:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

What Are The Top-Performing Regions Within The Corifact Market?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Corifact Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795